Serum free light chain assays now on Roche cobas 6000
New Freelite® assays for measuring free kappa and free lambda immunoglobulin light chain levels in serum have been developed for use on the Roche cobas 6000. When run on these cobas c systems the new 100 test Freelite® kits provide an automated, quantitative and more sensitive assay, compared to traditional methods, for the diagnosis, prognosis and monitoring of monoclonal gammopathies.
The addition of Freelite® for the cobas 6000 to the product range means that the award winning Freelite® serum free light chain assays are now available on the majority of popular nephelometric and turbidimetric analysers used in clinical laboratories.
Freelite® has proved to be a major breakthrough for the detection and monitoring of Multiple Myeloma (MM) and other B-cell dyscrasia. There is now significant clinical evidence indicating the benefit of serum free light chain assays in initial screening for monoclonal gammopathies, identifying AL amyloidosis and Nonsecretory MM patients missed by conventional electrophoretic methods, as a prognostic indicator for progression in myeloma, for risk stratification of MGUS patients and rapid evaluation of treatment efficacy.
For more information follow the links above to the Freelite® website or contact us.